Reports Q3 revenue $214,000, consensus $1.33M. “Our focus continues to be the clinical development of BXCL501,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics (BTAI). “We are advancing our SERENITY At-Home trial to pursue the near-term growth opportunity for treating acute agitation associated with bipolar disorders or schizophrenia in the outpatient setting. At the same time, we are progressing with our TRANQUILITY In-Care trial planning for Alzheimer’s-associated agitation. We are driven by the needs of patients, caregivers, and healthcare providers, as well as the market-expansion potential of our lead neuroscience asset.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics advances Phase 3 trials of BXCL501
- BTAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioXcel Therapeutics price target lowered to $5 from $7 at H.C. Wainwright
- BioXcel Therapeutics announces DOD grant to UNC to fund study of BXCL501
- Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant